Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from China Shineway Pharmaceutical Group Limited ( (HK:2877) ) is now available.
China Shineway Pharmaceutical Group Limited reported a 16.4% decrease in sales revenue for 2024, with a net profit decline of 13.4%, reflecting challenges in the TCM industry due to policy changes and market competition. Despite these challenges, the company maintained stable profitability by optimizing production processes and enhancing market competitiveness. The TCM industry is poised for growth with national support and reforms, offering new opportunities for transformation and development.
More about China Shineway Pharmaceutical Group Limited
China Shineway Pharmaceutical Group Limited operates in the pharmaceutical industry, focusing on traditional Chinese medicine (TCM) products. The company is involved in the production and distribution of TCM and formula granules, with a market focus on enhancing the TCM industry chain and adapting to evolving healthcare policies.
YTD Price Performance: -10.16%
Average Trading Volume: 1,103,118
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$6.4B
See more data about 2877 stock on TipRanks’ Stock Analysis page.